Why the study?
Inter-atrial block is associated with atrial fibrillation and adverse events in various populations, but its prognostic impact in HFpEF remains unknown.
Does the presence of inter-atrial block (IAB) predict adverse events in patients with HFpEF?
Does the presence of inter-atrial block (IAB) predict adverse events in patients with HFpEF?
Progressive stages of electrical atrial dysfunction, such as inter-atrial block, are strong prognostic markers for adverse outcomes in patients with HFpEF.
Answers are grounded in this paper and cite their sources.
IAB signals elevated risk in HFpEF; leaves open its role in risk stratification or trial enrichment.
AIMS: Inter-atrial block (IAB), a marker of electrical atrial dysfunction, is associated with an increased risk of atrial fibrillation (AF) and adverse events in various populations. The prognostic impact of IAB in heart failure (HF) with preserved ejection fraction (HFpEF) remains unknown. The aim of this study is to determine the prevalence of IAB and the association of IAB and AF with adverse events in HFpEF across different healthcare settings. METHODS AND RESULTS: (HR 3.8 [95% CI 1.8-8.1], P < 0.001). CONCLUSIONS: Progressive stages of electrical atrial dysfunction appeared to be prognostic markers of adverse outcomes in ambulatory and recently hospitalised patients with HFpEF. Ambulatory patients with HFpEF and no early stages of electrical atrial dysfunction showed to be at very low risk for adverse outcomes. Whether such patients benefit less strict management remains to be investigated.
No takes yet. Share an insight, caveat, or question.
Weerts et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: